BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:U.S. CDMRP – Spinal Cord Injury Research Program | Research Fund
 ing
DTSTART;VALUE=DATE:20260803
DTSTAMP:20260611T114847Z
UID:13d9dc64e95138322b28a27b455760db223a6f0a9f3670fd50f58aae
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the 2026 Spinal Cor
 d Injury Research Program (SCIRP) Awards. Several award programs are avail
 able:\n\n	The Clinical Trial Award supports the rapid implementation of cl
 inical trials with the potential to have a significant impact on the treat
 ment or management of spinal cord injury (SCI). Proposed projects may rang
 e from small proof of-concept trials (i.e.\, pilot\, first-in-human\, phas
 e 0) to demonstrate the feasibility or inform the design of more advanced 
 trials through large scale trials to determine efficacy in relevant patien
 t populations.\n	The Clinical Translation Research Award supports high-imp
 act\, new or emerging clinical research that requires additional prelimina
 ry studies\, such as feasibility\, pilot\, or optimization\, to prepare fo
 r future larger-scale clinical trials or implementation.\n	The Translation
 al Research Award supports translational research that will accelerate the
  movement of promising ideas in SCI research into clinical applications. A
 pplications may include preclinical evaluations of interventions and/or cl
 inical studies involving human subjects and human anatomical substances.\n
 	The Investigator-Initiated Research Award supports studies that have the 
 potential to make an important contribution to SCI research\, patient care
  and/or quality of life. Permitted research includes preclinical studies i
 n animal models\, research with human subjects or human anatomical substan
 ces\, as well as ancillary studies associated with an existing clinical tr
 ial.\n\nAll applications must address at least one of the program Priority
  Areas and undertake an associated near-term Programmatic Goal. The FY26 S
 CIRP Priority Areas with Programmatic Goals are listed at the end of this 
 announcement.\n\nFunding:      \nClinical Trial Award: $4.8M – $4.9
 6M\nClinical Translation Research Award: $2.00M - $2.16M\nTranslational Re
 search Award: $2.00M - $2.16M\nInvestigator-Initiated Research Award: $800
 K-$900K\nNote: Cost caps are total costs (direct plus indirect costs). I
 n accordance with EPFL guidelines\, budgets should include a 20% overhead\
 , and the total budget must remain within the grant’s maximum allowable 
 funding\n\nDuration:\nClinical Trial Award: 4 years\nClinical Translation 
 Research Award: 3 years\nTranslational Research Award: 3 years\nInvestigat
 or-Initiated Research Award: 3 years\n\nEligibility: Applicants from inter
 national organizations or institutions are eligible to apply\, and there a
 re no citizenship restrictions. Independent investigators at all career le
 vels are eligible.\n\nHow to Apply: Pre-applications are submitted through
  the eBRAP platform. They should contain contact information\, a letter of
  intent\, and a list of collaborators and key personnel as suggested on th
 e platform. Full applications will be made via a Grants.gov workspace.\n\n
 Pre-Application Deadline:           \n03 August 2026\, 5:00 p.m.
  Eastern time\n\nFull Application Deadline:          \n12 Novembe
 r 2026\, 11:59 p.m Eastern Time\n\nFurther information:\n\n\n	To find the 
 full program announcements and to start your pre-application see here\n	A 
 useful summary of each call can be found here\n	For questions about the eB
 RAP or Grants.gov platforms\, contact the Research Office.\n	Grants.gov Fu
 nding Opportunity Numbers:\n	\n		Clinical Trial Award: HT942526SCIRPCTA\n	
 	Clinical Translation Research Award: HT942526SCIRPCTRA\n		Translational R
 esearch Award: HT942526SCIRPTRA\n		Investigator-Initiated Research Award: 
 HT942526SCIRPIIRA\n	\n	\n\n\nFY26 SCIRP Priority Areas With Programmatic G
 oals:\n\nPriority Area: Acute Injury Intervention \n\n\n	Near-Term Goal: D
 evelop and/or test interventions\, e.g.\, surgical\, device\, pharmacologi
 c\, that protect spinal cord tissue from further damage shortly after inju
 ry and can be administered on a timeline suitable for acute trauma care in
  both battlefield and civilian settings.\n	Long-Term Goal: Adoption of man
 agement/stabilization practices into the standard of care for acute spinal
  cord injury\, leading to meaningfully improved outcomes within the prehos
 pital\, hospital\, or deployed environments.\n\n\nPriority Area: Secondary
  Health Effects \n\n\n	Near-Term Goal: Develop and/or test interventions t
 o prevent or manage the secondary health effects of spinal cord injury tha
 t impact injury survivors throughout their lifespan.\n	Long-Term Goal: Ado
 ption of interventions into the standard of care that significantly reduce
  the burden of secondary health effects and improve the lifelong health of
  SCI survivors.\n\nPriority Area: Psychosocial Well-Being \n\n\n	Near-Term
  Goal: Develop and/or test psychosocial interventions that are specificall
 y tailored to the unique needs of individuals with SCI\, their families\, 
 and/or care partners.\n	Long-Term Goal: Adoption of interventions into the
  standard of care that promote psychosocial well-being for people with SCI
 \, their families\, and/or care partners.\n\nPriority Area: Rehabilitation
  and Regeneration \n\n\n	Near-Term Goal: Develop and/or test rehabilitatio
 n\, regenerative\, or neuroplastic interventions for individuals with spin
 al cord injury that can be implemented at any stage of life post-injury.\n
 	Long-Term Goal: Adoption of validated rehabilitation and regenerative the
 rapies into the standard of care that meaningfully improve function\, inde
 pendence\, and quality of life after SCI.\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR